FDA Approved: KALBITOR — Supplemental Application (Takeda Pharmaceuticals America, Inc.)

View source ↗

Summary

The FDA approved a supplemental application for Kalbitor (ecallantide) from Takeda Pharmaceuticals America, Inc. Kalbitor treats hereditary angioedema.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hereditary Angioedema

Drugs mentioned

• KALBITOR (ecallantide)

Snippet

SUPPL AP for KALBITOR (ECALLANTIDE)